Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non Operating Investment Income (2024)

Day One Biopharmaceuticals (DAWN) has disclosed Non Operating Investment Income for 1 consecutive years, with $108.0 million as the latest value for Q2 2024.

  • On a quarterly basis, Non Operating Investment Income changed N/A to $108.0 million in Q2 2024 year-over-year; TTM through Sep 2025 was $108.0 million, a 0.0% change, with the full-year FY2024 number at $108.0 million, changed N/A from a year prior.
  • Non Operating Investment Income was $108.0 million for Q2 2024 at Day One Biopharmaceuticals.
  • In the past five years, Non Operating Investment Income ranged from a high of $108.0 million in Q2 2024 to a low of $108.0 million in Q2 2024.